Increasing evidence suggests that the non-canonical IKKs perform essential roles in tumor genesis and development leading to the notion that non-canonical IKKs may be good targets for cancer therapy. and VEGF manifestation. Most importantly these TBK1/IKKi dual inhibitors have drug-like properties including low molecular excess weight low Cytochrome P450 inhibition and high metabolic stability. Therefore… Continue reading Increasing evidence suggests that the non-canonical IKKs perform essential roles in